SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

$HYPR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $HYPR alert in real time by email
SC 13G/A 1 tm22331061_sc13ga.htm SC 13G/A

 

 

 

SECURITIES & EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

 

(Amendment No. 1)*

 

 

 

Hyperfine, Inc.
(Name of Issuer)

 

Class A common stock

(Title of Class of Securities)

 

44916K106

(CUSIP Number)

 

December 31, 2021**

(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨       Rule 13d-1(b)

 

¨       Rule 13d-1(c)

 

x      Rule 13d-1(d)

 

(Page 1 of 9 Pages)

 

 

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

** This Amendment No. 1 to Schedule 13G is being filed to correct the number of Class A Shares reported as beneficially owned by the Reporting Persons as of December 31, 2021, to include 100,000 shares held through HC Affiliates and 591,650 shares held in separately managed accounts that were inadvertently omitted from the original statement.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 44916K106 13G Page 2 of 9 Pages

 

(1)

NAMES OF REPORTING PERSONS

 

HC Sponsor LLC 

(2)

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

(a) ¨         (b) ¨

(3) SEC USE ONLY
(4)

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands 

NUMBER OF
SHARES
BENEFICIALLY OWNED BY
EACH
REPORTING
PERSON WITH
(5)

SOLE VOTING POWER

 

0 

(6)

SHARED VOTING POWER

 

6,634,000(1) 

(7)

SOLE DISPOSITIVE POWER

 

0 

(8)

SHARED DISPOSITIVE POWER

 

6,634,000(1) 

(9)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

6,634,000(1) 

(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
(11)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

12.0%(2) 

(12)

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,100,000 Class A Shares held by the HC Affiliates.

 

(2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

 

 

 

CUSIP No. 44916K106 13G Page 3 of 9 Pages

 

(1)

NAMES OF REPORTING PERSONS

 

HealthCor Group, LLC 

(2)

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

(a) ¨         (b) ¨

(3) SEC USE ONLY
(4)

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware 

NUMBER OF
SHARES
BENEFICIALLY OWNED BY
EACH
REPORTING
PERSON WITH
(5)

SOLE VOTING POWER

 

0 

(6)

SHARED VOTING POWER

 

6,634,000(1) 

(7)

SOLE DISPOSITIVE POWER

 

0 

(8)

SHARED DISPOSITIVE POWER

 

6,634,000(1) 

(9)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

6,634,000(1) 

(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
(11)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

12.0%(2) 

(12)

TYPE OF REPORTING PERSON (see instructions)

 

OO

 

(1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,100,000 Class A Shares held by the HC Affiliates.

 

(2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

 

 

 

CUSIP No. 44916K106 13G Page 4 of 9 Pages

 

(1)

NAMES OF REPORTING PERSONS

 

Arthur Bruce Cohen

(2)

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

(a) ¨         (b) ¨

(3) SEC USE ONLY
(4)

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF
SHARES
BENEFICIALLY OWNED BY
EACH
REPORTING
PERSON WITH
(5)

SOLE VOTING POWER

 

0 

(6)

SHARED VOTING POWER

 

7,225,650(1) 

(7)

SOLE DISPOSITIVE POWER

 

0 

(8)

SHARED DISPOSITIVE POWER

 

7,225,650(1) 

(9)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,225,650(1) 

(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
(11)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

13.1%(2) 

(12)

TYPE OF REPORTING PERSON (see instructions)

 

IN

 

(1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC, 1,100,000 Class A Shares held by the HC Affiliates and 591,650 Class A Shares held by separately managed accounts.

 

(2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

 

 

 

CUSIP No. 44916K106 13G Page 5 of 9 Pages

 

(1)

NAMES OF REPORTING PERSONS

 

Joseph Patrick Healey

(2)

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

(a) ¨         (b) ¨

(3) SEC USE ONLY
(4)

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF
SHARES
BENEFICIALLY OWNED BY
EACH
REPORTING
PERSON WITH
(5)

SOLE VOTING POWER

 

0 

(6)

SHARED VOTING POWER

 

7,225,650(1) 

(7)

SOLE DISPOSITIVE POWER

 

0 

(8)

SHARED DISPOSITIVE POWER

 

7,225,650(1) 

(9)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,225,650(1) 

(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
(11)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

13.1%(2) 

(12)

TYPE OF REPORTING PERSON (see instructions)

 

IN

 

(1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC, 1,100,000 Class A Shares held by the HC Affiliates and 591,650 Class A Shares held by separately managed accounts.

 

(2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

 

 

 

CUSIP No. 44916K106 13G Page 6 of 9 Pages

 

Item 1(a). Name of Issuer:
   
  Hyperfine, Inc.  
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
  351 New Whitfield Street
Guilford, CT 06437
   
Item 2(a, b, c). Names of Persons Filing:
   
  (i) HC Sponsor LLC, 55 Hudson Yards, 28th Floor, New York NY 10001;
     
  (ii) HealthCor Group, LLC, 55 Hudson Yards, 28th Floor, New York NY 10001;
     
  (iii) Joseph Healey, 55 Hudson Yards, 28th Floor, New York, NY 10001;
     
  (i) Arthur Cohen, 12 South Main Street, #203 Norwalk, CT 06854;
     
  Both Mr. Healey and Mr. Cohen are United States citizens.
   
  The persons at (i) through (iv) above are collectively referred to herein as the “Reporting Persons”.

 

 

 

CUSIP No. 44916K106 13G Page 7 of 9 Pages

 

Item 2(d). Title of Class of Securities
   
  Class A common stock
   
Item 2(e). CUSIP Number
   
  44916K106
   
Item 3. Not applicable.
 
Item 4.Ownership.
    
(a)Amount beneficially owned:
 See responses to Item 9 on each cover page.
(b)Percent of Class:
 See responses to Item 11 on each cover page.
(c)Number of shares as to which the Reporting Person has:
   (i)Sole power to vote or to direct the vote:
   See responses to Item 5 on each cover page.
  (ii)Shared power to vote or to direct the vote:
   See responses to Item 6 on each cover page.
  (iii)Sole power to dispose or to direct the disposition of:
   See responses to Item 7 on each cover page.
  (iv)Shared power to dispose or to direct the disposition of:
   See responses to Item 8 on each cover page.

 

HC Sponsor LLC (the “Sponsor”) directly holds 5,534,000 Class A Shares (the “Founder Shares”) and entities affiliated with the Sponsor (the “HC Affiliates”) directly hold 1,100,000 Class A Shares, of which 1,000,000 Class A Shares were purchased in a private placement (the “PIPE Shares”). The Sponsor is managed by its manager, HealthCor Sponsor Investments LLC, which is managed by its manager, HealthCor Group, LLC, which also indirectly manages the HC Affiliates. Arthur Cohen and Joseph Healey are the controlling members of HealthCor Group, LLC. In addition, separately managed accounts (the “SMAs”) managed by HealthCor Management, L.P. own 591,650 Class A Shares. Messrs. Cohen and Healey are the managers of the general partner of HealthCor Management, L.P. As such, Messrs. Cohen and Healey have voting and investment discretion with respect to the securities held by each of HC Sponsor LLC, the HC Affiliates and the SMAs but disclaim beneficial ownership of such securities. The filing of this Statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by this Statement.

 

Item 5.Ownership of Five Percent or Less of a Class:
  
 If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

 

 

 

CUSIP No. 44916K106 13G Page 8 of 9 Pages

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  Not Applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group.
   
  See Exhibit I.
   
Item 9. Notice of Dissolution of Group.
   
  Not Applicable
   
Item 10. Certification.
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Exhibits:

 

Exhibit I:Joint Acquisition Statement

 

 

 

CUSIP No. 760873109 13G Page 9 of 9 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DATED: December 20, 2022

 

  HC Sponsor LLC
     
    /s/ Arthur Cohen
    Name: Arthur Cohen
    Title: Authorized Signatory
     
  HealthCor Group, LLC
     
    By: HealthCor Group, LLC, its general partner
     
    /s/ Arthur Cohen
    Name: Arthur Cohen
    Title: Authorized Signatory
     
  JOSEPH HEALEY, Individually
    /s/ Joseph Healey
     
  ARTHUR COHEN, Individually
    /s/ Arthur Cohen

 

 

 

EXHIBIT I

 

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated:         December 20, 2022

 

  HC Sponsor LLC
     
    /s/ Arthur Cohen
    Name: Arthur Cohen
    Title: Authorized Signatory
     
  HealthCor Group, LLC
     
    By: HealthCor Group, LLC, its general partner
     
    /s/ Arthur Cohen
    Name: Arthur Cohen
    Title: Authorized Signatory
     
  JOSEPH HEALEY, Individually
    /s/ Joseph Healey
     
  ARTHUR COHEN, Individually
    /s/ Arthur Cohen

 

 

 

Get the next $HYPR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HYPR

DatePrice TargetRatingAnalyst
8/11/2022$8.00 → $2.40Overweight → Equal Weight
Wells Fargo
5/31/2022$7.00Outperform
Evercore ISI
4/14/2022$8.00Overweight
Wells Fargo
More analyst ratings

$HYPR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. "I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025," said Maria Sainz, Chief Executive Officer and President of Hyperfine,

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation

    Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and accelerated computing to enhance Hyperfine portable imaging technology—making brain MRI faster, smarter, and more affordable on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317452571/en/The AI-powered

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HYPR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HYPR
SEC Filings

See more

$HYPR
Leadership Updates

Live Leadership Updates

See more
  • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments
  • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

    Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Financials

Live finance-specific insights

See more
  • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

    GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more